Business, energy, technology, markets and global industry news from Business News Today

Oczyesa

PharmaDeviceNews Oczyesa
Camurus has secured a December 18, 2026 FDA decision date for CAM2029 in acromegaly, but manufacturing compliance remains the decisive hurdle to US approval. Representative image.
Pharma & Biotech

CAM2029 is back before the FDA, but has Camurus finally cleared its manufacturing hurdle?

Camurus has restored a formal United States review timeline for CAM2029, but the December decision remains tied to third-party manufacturing compliance rather than new questions about clinical efficacy.

Read More
Representative image of acromegaly drug development as Camurus’ Oclaiz FDA setback puts rare disease manufacturing risk, long-acting injectable therapies, and U.S. regulatory scrutiny under sharper focus.
Pharma & Biotech

Camurus Oclaiz CRL shows how one manufacturing site can stall a differentiated endocrine therapy

Find out how Camurus’ fresh FDA setback for Oclaiz could delay its U.S. acromegaly launch and reshape rare disease manufacturing risk.

Read More